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AbstrAct:
In line with the increase in the number of older people in the world, the focus of scientists is directed 
at examining mechanisms of the aging process as well as establishing strategies/interventions in order 
to slow down aging and achieve longevity. On preclinical testing models, the most effective strategy 
for this purpose, as well as for the purpose of delaying age-related diseases, nutritional interven-
tion- restriction of calorie (CR) has been demonstrated, but also some alternative forms of calorie 
restriction. Possible undesirable effects of restriction are still in the testing phase, and it is known that 
it is generally difficult to implement in humans. Therefore, the new area of research in gerontology 
has become the discovery and examination of the effects of compounds that mimic the effects of 
caloric restriction, so called caloric restriction mimetics (CRM). These compounds include numerous 
compounds of natural origin but also approved medicaments with certain indications. This overview 
summarizes the latest data on known mechanisms of caloric restriction and more familiar caloric 
restriction mimetics. 
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Sažetak:
Starenje, kalorijske restrikcije i kalorijsko restrikcijska mimetrika
U skladu s povećanjem broja starijih ljudi u svijetu, fokus znanstvenika usmjeren je na ispitivanje me-
hanizama procesa starenja kao i na uspostavljanje strategija / intervencija kako bi se usporilo starenje i 
postigla dugovječnost. Na predkliničkim modelima ispitivanja, najučinkovitija strategija za ovu svrhu, 
kao i za odgađanje bolesti povezanih s dobi, pokazana je prehrambena intervencija - ograničenje kalo-
rija, ali i neki alternativni oblici ograničavanja kalorija. Mogući neželjeni učinci restrikcije još su u fazi 
ispitivanja, a poznato je da je to općenito teško provesti kod ljudi. Stoga je novo područje istraživanja 
u gerontologiji postalo otkriće i ispitivanje učinaka spojeva koji oponašaju učinke kalorijske restrikci-
je, takozvane mimetike kalorijske restrikcije. Ti spojevi uključuju brojne spojeve prirodnog podrijetla, 
ali i odobrene lijekove s određenim indikacijama. Ovaj pregled sažima najnovije podatke o poznatim 
mehanizmima kalorijskog ograničenja i poznatijim mimeticima za ograničenje kalorija.
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introduction
Aging is an inexorable, complex and progressive but natural process 
that results in persistent worsening of the functioning of the body and 
increased morbidity and mortality. As a result of improved health care, 
the rate of the elderly population is steadily rising in most developed 
countries and is one of the biggest social challenges of today. Among 
other things, the process is associated with cellular senescence, short-
ening telomeres, genomic instability, epigenetic changes, intercellu-
lar communication changes, mitochondrial dysfunction, stem cell 
depletion, chronic inflammation, loss of protease and the like1. Figure 
1 shows some of the factors contributing to aging progression and 
age-related diseases. 
All these changes also increase the tendency of the elderly toward 
various pathological conditions, which are most commonly associated 
with persistent chronic inflammation3. Therefore, the primary focus 
of modern medicine is the treatment of specific age-related diseases. 
In the scientific community, more than 300 theory of aging processes 
are discussed, and the theory of oxidative stress seems to be the most 
comprehensive4. According to the Blagosklonny and Hall propos-
als, aging can be understood, for example, as “a type of unregulated 
continuation of normal developmental processes and related cellular 
programs with special emphasis on growth”5, and this theory is com-
plemented by inflammatory aging theory6. Inflammation occurring in 
older people is defined as subclinical, chronic and sterile one, with the 
accumulation of senescent cells, characterized by pro-inflammatory 
secretory phenotype7.
However, prolonged life expectancy does not yet imply a healthy life 
span since aging is associated with a number of chronic diseases, such 
as diabetes, cancer, cardiovascular and neurodegenerative diseases8. 
Furthermore, the greater prevalence of age-related diseases is necessari-
ly reflected in the cost of health care. Therefore, the scientific commu-
nity around the world makes significant efforts to discover strategies 
for achieving so-called healthy, but also active aging. The term “Active 
Aging” includes the optimization of various opportunities for health, 
participation in life processes and the necessary security, all to improve 
the Quality of Life  of older individuals9. Research in the field of aging 
is largely carried out on laboratory models and is directed towards 
various genetic and pharmacological interventions in the aging process 
itself10. Although they have been going on for decades, the translating 
of the obtained results into the human population is still questionable.
Interventions for the purpose of healthy aging and longevity should 
include the attenuation or deceleration of some, if not all, already 
mentioned molecular-cellular changes, which include the aging pro-
cess, the processes of inducing pathology associated with aging, and in 
particular, processes of deregulated sensing of nutrients or energy1. It 
has been shown that various interventions, including genetic manipu-
lation, some drugs implementation and calorie limitation, extend the 
lifespan of several experimental models11. The superiority of some of 
these strategies in extending life expectancy has not been known until 
recently. However, the meta analysis of the published studies with 
Caenorhabditis and Drosophila, using the appropriate algorithm, 
emphasized the overall advantage of calorie (or energy) restriction 
(CR) in slowing down the aging process and prolonging the lifespan12. 
It is therefore considered that more acceptable, anti-aging strategies, 
are those strategies that include environmental factors, to reduce the 
number of risk factors of bad health13. Accordingly, one of the leading 
concepts of gerontology is a non-genetic, non-pharmacological CR 
strategy or a reduction in food intake, but without undernutrition, i.e. 
CR with optimal nutrition. The concept is not new, as through the 
history numerous communities promoted health benefits of dietary 
restrictions, including the ancient Greeks and Romans. Numerous 
studies, mainly on various model organisms, have shown that CR 
slows aging, prolongs the period of healthy life, postpones the onset 
of various age-related diseases and prolongs life expectancy14,15. CR as 
the idea of encouraging longevity originates from 1917 by Osborne 
et al. (16), who noticed after restriction of food in the rats, a reduced 
growth but extended life span. Later, this association was experimen-
tally verified and confirmed by numerous research groups on animal 
models ranging from fungi to mammals17,18. Research results on 
non-human primates19 are consistent with other models.
Because of the ethical limitations there are a small number of studies 
on the human sample (mostly epidemiological studies are conducted. 
Results of one of the few researches on the human sample, Compre-
hensive Assessment of Long Term Effects of Reducing Caloric Intake 
Energy Research (CALERIE)20, confirmed the results of Biosphere 2 
21, i.e. a previously conducted two-year study of some anti-aging ef-
fects22. However, some undesirable effects of CR  have been identified 
in this and other studies23,24. Given the possibility of the unwanted 
effects of long-lasting CR, questionable adhering to CR regime 
throughout life or for a long time, newer research as an alternative 
strategy involves the detection and development of CR mimetics 
(CRMs). This concept was first introduced by Lane et al. in 1998, 
proposing 2-deoxy-D-glucose (2DG) as CRM25.
The data selected for this review were collected by searching the 
PubMed database, by the use of the following terms: lifespan, aging, 
healthspan, caloric restriction, dietary restriction, CR-mimetics. The 
focus of this paper is the possible CR mechanisms and the more 
familiar CRM. Additional searches were made in accordance with 
the names of specific pathways and pharmacological agents. Arti-
cles published in English between 2000 and 2019 were included. A 
limited number of selected articles and reviews is in accordance with 
the guidelines of the journal. We apologize to the authors of other ex-
cellent review articles that are not included in the text for this reason.
calorie reStriction
Calorie restriction (or energy restriction) means reduced caloric 
intake, less than 20% (mild CR) and 50% (severe CR) than the body 
needs26  or reduced intake of food but without malnutrition. Nu-
 Figure 1. Some features that contribute to aging prosess and age-related diseases. 
Modified according to reference (2).
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merous studies have shown that CR induces pleiotropic, favorable 
changes in terms of longevity and extension of healthy life span, or 
postponement of the beginning of age-related diseases, regardless of 
whether CR is short or long-term practice. These include postpone-
ment of sarcopenia, brain atrophy, protection from arthritis and 
cardiovascular disease, prevention of age-related diabetes, reduction 
of incidence and progression of cancer, protection of colon health, 
maintenance of cognitive functions, etc.27 Also, CR includes changes 
such as: modulation of important regulatory pathways through ex-
pression and stimulation the activity of key enzymes of metabolism, 
decreased oxidative damage of important biomolecules, increased an-
tioxidative defense, modulation of mitochondrial activity, enhanced 
clearance of degraded biomolecules, reduction of chronic inflamma-
tion, control of cell repair mechanisms on molecular (eg. DNA re-
pair, protein repair, membrane lipid repair), subcellular (autophagy), 
cellular and tissue levels (apoptosis) etc.28
Generally practiced CR methods include reduced consumption of 
food, change of nutritional ingredients, digestion inhibition and ab-
sorption of nutritional ingredients, inhibition of appetite and satiety 
and CRMs28. The implementation of the CR regime in the general 
human population is bad and may be unsafe for some persons, 
depending on their age or body weight. Long-lasting CR can, in fact, 
result in malnutrition, so the effects of CR variants, eg. Intermittent 
Fasting Diatery restriction (IF-DR), or occasionally starvation (every 
other day) are also tested. Due to the occasional nature of fasting, IF-
DR approach seems to relieve the constant hunger effect, experienced 
by CR practitioners 29. Some studies show that reduced intake of 
protein sources without calorie change30 or even restriction of certain 
amino acids, such as methionine or tryptophan31, has a similar effect 
as CR. This has in some ways set the CR intervention questionable, 
because these interventions include restrictions on nutrition, but not 
in calories. More recently, the term dietary restriction - DR32, which 
can, as mentioned above, includes various feeding regimes (alternate 
starvation day, intermittent starvation, change in dietary intake).  A 
large number of studies, on the other hand, are also aimed at assess-
ing the efficacy of natural and/or pharmacological compounds that 
mimic the effects of CR, i.e. CRM.
MechaniSMS of calorie reStriction
The cellular energy balance, essential for normal functioning of 
the organism, is associated with several key energy and nutritional 
pathways. They are also involved in the emergence of physiological 
dysfunction that occurs with aging. CR promotes already men-
tioned life-sustaining processes, and CR effects mechanisms include  
nutrient and energy status sensors, enzymes from the group of 
kinase and deacetylase, involved in post-translational modifications, 
signal cascades/pathways and transcription factors and coactivators 
necessary for the metabolic balance maintenance process. In many 
experimental models, several nutrient-sensing signaling pathways are 
described, such as insulin-like growth factor-1, IGF-1:, mechanistic 
Target-of-Rapamycin, mTOR; Adenosine Monophosphate-Activated 
Protein Kinase, AMPK; and some Sirtuin (SIRT) family members 
(especially SIRT-1) are cosidered essential for CR27. The core features 
of these factors  are briefly listed in this section. At certain process 
levels there are interactions of these signal pathways, sharing many 
downstream targets that regulate cellular processes associated with 
aging, but also with CR33.
Mechanistic (or mammalian) Target of Rapamycin is a serine/
threonine protein kinase involved in various physiological processes 
(cell metabolism, cell survival, cell growth, autophagy), an activity 
that can be inhibited by the immunosuppressive drug rapamycin34. It 
is also a key regulator of cell growth and metabolism that integrates 
multiple signal pathways linked, among other things to cellular 
energy, nutrient availability and stress35. There are two structurally 
and functionally different protein mTOR-complexes: mTORC1 and 
mTORC2 36 that are linked to protein synthesis, autophagy, lipid 
metabolism. mTORC1 is the primary modulator of protein, lipid 
and nucleotide synthesis, autophagy, mitochondrial metabolism and 
is largely regulated by the availability of nutrients, growth factors, 
energy, and stress levels. It seems that mTORC1 activation in higher 
organisms also requires the presence of insulin and IGF-137. The most 
well-known downstream goals of mTOR are ribosomal protein S6 ki-
nase 1 (S6K1), and eucariotic translation initiation factor, 4E-binding 
protein 1 (4EBP1)38. Although mTOR is not a direct transcription 
regulator, it regulates a number of transcription factors, eg. NF-κB 
(inflammation), peroxisome proliferator-activated receptor-κ, PPARκ 
(adipogenesis), transcription factor EB (TFEB, autophagy) and oth-
ers39. mTORC2 is involved in metabolism modulation, cytoskeletal 
dynamics, cell survival control, but its regulation is less known40.
Harrison et al. were the first who discovered the association of inhib-
itory activity of rapamycin on mTOR and prolongation of lifespan 
of genetic heterogeneous mice41, as confirmed by further studies. 
Detailed explanation of the mechanisms of this connection still does 
not exist, but it is assumed to include these downstream effectors of 
mTOR such as S6K1 and 4E-BP42 and, for example, autophagy acti-
vation43, self-regeneration of some stem cells44, resistance to different 
types of stress and suppression of inflammatory cytokine secretion 
from the senescent cell45. 
Inhibition of mTOR signaling, with rapamycin or nutritional inter-
ventions, thus protects against metabolic dysfunction, neurodegener-
ation and cancer, and leads to an increase in lifespan in various model 
organisms (yeasts, flies and C. elegans), while increased mTOR 
signaling is included in pathogenesis of several age-related diseases, 
such as type 2 diabetes mellitus and cancer46. Unlike other signaling 
pathways (AMPK and SIRT-1) as an energy sensors, mTOR activity 
is therefore inhibited by reducing the availability of nutrients in order 
to preserve energy reserves.
AMP-activated protein kinase. The cells provide energy by degra-
dation of adenosine triphosphate (ATP) into adenosine diphosphate 
(ADP) and inorganic phosphate in mitochondria, whereby the rate 
of synthesis and ATP consumption coincides with the maintenance 
of the energy balance required for normal cellular processes. With 
this goal, during a low energy availability period, cells are rapidly 
replenishing ATP storage by enzymatic coupling of two ADPs, with 
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adenosine monophosphate (AMP) as a byproduct. This compound is 
an important signaling molecule for sensing a low energy status of the 
cell by activating the AMP-activated protein kinase (AMPK) enzyme. 
The enzyme acts by phosphorylation of numerous downstream pro-
tein targets and transcription regulators that return the cellular energy 
balance47 by activating the catabolism processes (eg. glycolysis, fatty 
acid oxidation) and suppressing anabolic processes (eg. protein and 
fatty acid synthesis). For example, AMPK regulates cellular glucose 
utilization, glucose transporter concentration 4, fatty acid κ-oxidation, 
mitochondrial biogenesis, etc.
AMPK is associated with food intake, and is the key intracellular en-
ergy sensor in cells. It is activated when the AMP/ATP ratio in the cell 
is increased, as occurs when cells are deprived of glucose48. The AMPK 
therefore recognizes the available amount of energy and consequently 
regulates other pathways important in the aging process (SIRT-1 is a 
positive regulator and mTOR is a negative regulator). This is a way 
to inhibit energy-consuming processes and activate processes that 
generate energy to maintain energy homeostasis. It is described that 
AMPK also directly phosphorylates PGC-1κ (peroxisome proliferator 
activated receptor-gamma coactivator 1-κ) transcriptional co-activator 
of nuclear receptor transcription factors. On that way it promotes 
lipid utilization as fuel, as well as various FoxO (Forkhead box 03) 
family of proteins acting as AMPK-induced autophagy mediators49. 
AMPK is a heterotrimeric protein, constructed of one κ-catalytic 
subunit and two regulatory κ- and κ- subunits. Under low ATP con-
ditions, AMP or ADP binds to the regulatory κ-subunit, resulting in 
a conformational change that protects the activating phosphorylation 
of AMPK50.
Sirtuins. In addition to regulating the aging process, sirtuins (SIRTs) 
are involved in CR-induced longevity. They are the enzyme family 
of nicotinamide adenine dinucleotide (NAD+)-dependent histone 
deacetylase, that affect various cellular activities. Among others, they 
regulate energy metabolism, stress resistance, cell fate determina-
tion, mitochondrial biogenesis, inflammation suppression, genomic 
stability and longevity. At the same time they interfere with different 
factors51. Sirtuins correspond to NAD+/NADH cellular fluctuations. 
Figure 2. Postulated mechanisms of action of calorie restriction (CR), adapted according to reference ( 55). IGF-1 (insulin-like growth factor-1); PI3K/AKT (phosphati-
tylinositol kinase/protein kinese B); PDK1 (phosphoinositide-dependent kinase- 1); S6K (S6 protein kinase); FoxO (forhead box protein); AMPK (AMP-dependent kinase); 
PGC1α (peroxisome proliferator-activated receptor α- coactivator 1-α) ; ATGs (autophagy related proteins); NQO1 (NAD(P)H dehydrogenase /quinone/-1); LKB1 (liver 
kinase B1); IGF-1; mTOR (mechanistic target of rapamycin): NF-αB (nuclear factor kappa B); IGF-1 patway (------); AMPK patway (- - - - -); Sirtuin patway ( )
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If there is not enough supply with nutrients, especially glucose, 
NAD+ will accumulate and then SIRTs will be activated. Deacetyl-
ation activity or removal of acetyl residues on numerous proteins, 
enzymes and transcription factors involved in key aspects of cellular 
physiology is related to NAD+ as a co-substrate. However, other 
activities of these enzymes, such as desukcinylation, demalonylation 
and depropionylation are also described. 
Seven sirtuin enzymes members (SIRT-1 to SIRT-7) were identi-
fied among the mammals, which are localized in different cellular 
compartmetns13,52. Sirtuin-1 is largely localized in the nucleus and, 
to a lesser extent, in the cytoplasm. It is most closely associated with 
mechanisms involved in aging and longevity, by deacetylating the 
main regulator of biogenesis PGC-1κ and transcriptional FoxO fac-
tor53. FoxO proteins are capable of increasing longevity by ensuring 
resistance to oxidative stress, protecting protein structures and pro-
moting lipid metabolism and autophagy15. Also, SIRT-1 deacetylates 
some glycolytic enzymes and transcription inducer hypoxia-inducible 
factor 1 thereby reducing the glycolysis process54.
Insulin-like growth factor. Insulin/IGF-1 pathway (IIS) of cellular 
signaling is hormone-regulated, and includes insulin, insulin-like 
peptides, receptor substrates and numerous downstream effectors33. 
Increased serum glucose concentration after food intake stimulate 
secretion of insulin hormones that activates IIS signaling. This signal-
ing pathway is also involved in modulating the aging process but also 
there are significant differences in this pathway depending on model 
organisms and mammalian species33,35. Activation or suppression of 
various dowstream effectors such as PI3/AKT/Ras (phosphatidyli-
nositol 3-kinase/protein kinase B/Ras), mTOR, S6K and transcrip-
tional FoxO and etc. are also involved in signaling this pathway 
during the CR regime33. CR, diet modulation, appropriate protein : 
carbohydrate ratio in diet, and reduced growth hormone contraction 
reduce the activity of IIS signaling, which is associated with health 
improvement and longevity of various species including human34,56. 
Due to reduced food intake during CR, signaling of this pathway 
is decreased, due to reduced insulin secretion and consequently the 
repression of FoxO factor13. The result is a more efficient response to 
stress because the transcription factor FoxO as an important target of 
the IIS pathway is involved in the induction of some stress response 
genes33,57.
In addition to the aforementioned main regulators of signaling 
pathways, some factors are also described which are also, at certain 
levels, associated with the participants of said signaling paths during 
CR. These are, for example, a) neuropeptide (NP) mediated by 
CR-induced autophagy process 57; b) PGC-1κ, a member of the 
transcription cluster family, participates in the process of mitochon-
drial biogenesis58; c) nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
59, which participates in increasing the expression of mitochondrial 
and cellular antioxidants; d) fibroblast growth factor 21 (FGF21) as 
an endocrine signal associated with metabolic control, whose value 
changes after low protein or methionine intake60. 
The described regulators and pathways of cellular energy and sensi-
tivity to nutrients can in particular modulate life expectancy, but as 
mentioned above, they are not exclusive to each other. They actually 
act synergistically in detecting changes in calorie/energy status in 
order to maintain cell homeostasis. For example, decreased availabil-
ity of macronutrients is one of the most common activators for the 
acivation of autophagy, partly by activating AMPK and SIRT-1, and 
by inhibiting mTOR signaling61. Figure 2 shows the simplified main 
regulators and network of CR participants.
Under CR conditions, the ratio of ATP/AMP is changed and the 
AMPK is activated. Cell metabolism changes, resulting in the 
accumulation of NAD+, which will lead to activation of SIRT-1. 
An antagonistic response involves inhibition of anabolic pathways 
mTOR and insulin/IGF1. Downstream factors/mediators can pro-
duce redundant effects that are reflected in processes such as prolifera-
tion balanced cell growth, increased autophagy/mitophagy, improved 
mitochondrial biogenesis, enhanced antioxidative defense, decreased 
inflammation, resulting in improved healthy and prolonged lifespan.
caloric reStriction MiMeticS
In model organisms of rodents and nonhuman primates, it has been 
shown that diet regimes in the form of dietary adaptation such as 
CR, have favorable effects on health and extend life62. Also, results 
on a human samples, eg. CALERIE, Biosphere 2 Study21, CRON 
Study62, show that moderate CR improves human health and reduces 
various metabolic factors associated with pathogenesis of chronic 
diseases. Serious or severe CR slows down the accumulation of mo-
lecular damage and thus maintains key physiological functions63. Still 
existing incompatibility of the results of the long-term studies of lon-
gevity has been attributed to differently designed examinations as well 
as to the composition and breeding of food64. In addition to the CR 
as a strategy for beneficial effects on health and thus the aging process 
of model organisms, alternative life-style strategies that mimic CR, as 
occasional and intermitent starvation, limitation of some amino acids 
or protein intake, etc.8 are described and discussion of the practicali-
ties and effects of such approaches are ongoing.
Despite the potential benefits of CR to improve physiological func-
tions in the aging process, most people are noncompliant to practice 
CR, or change nutritional routine for a long time. In other words, 
maintenance of CR with optimal nutrition is difficult to enforce in 
humans13. Furthermore, continuous CR represents a potential risk 
for older adults with normal weight who are already prone to loss 
of bone density and muscle mass. It is also described that reducing 
energy intake is aggravated by loss of skeletal muscle mass in older 
adults24, and adverse reactions such as sensitivity to cold, anemia, and 
depression62,65,66 are also reported in younger subjects. In restriktively 
fed animals, disorders in healing skin wounds67 and susceptibility to 
infections68 were observed.
In order to limit the risks of adverse effects of CR and take advantage 
of positive effects, over the past decade, significant attention has been 
paid to establishing more feasible approaches. The effects of com-
pounds and interventions that “mimic CR or starvation” are detected 
and tested, that is, without real CR regime. These are: a) pharma-
cological and nutritional compounds, CRM and b) CR mimicking 
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lifestyle (behavioural) approaches to lifestyle change69,70. 
According to Ingram et al., CRMs are considered compounds or ap-
proaches/procedures, that mimic the metabolic, hormonal and physi-
ological effects of CR, activate stress response paths that correspond to 
the level during CR (known under the term hormesis), enhance stress 
protection, produce CR-like effects on longevity, reduce the incidence 
of aging-related illnesses, maintain youth functions, and not reduce 
significantly, at least in the short run, food intake69. It is assumed 
that administration of mimetics that fulfill all or at least part of these 
criteria could have a positive impact on healthy life expectancy and 
longevity. In defining their effects, an important role will be to detect 
more reliable biomarkers of the aging process itself, since the existing 
ones still do not meet the criteria of an ideal biomarker71.
CR mimetics are classified according to mechanisms of action such 
as AMPK, SIRTs (NAD-boosting compounds included herein), 
autophagy activators and mTOR inhibitors. Of the already discovered 
compounds that have the potential to imitate CR effects, some in hu-
mans have clinical use with other indications. These are, for example, 
rapamycin (mTOR inhibitor), metformin (AMPK activator), and 
polyphenolic compound - resveratrol (AMPK and SIRT-1 activators) 
whose various properties are also frequently tested in human popu-
lations. Other compounds referred to as CRM potential compounds 
are: D-glucosamine glycosaminoglycan precursor and hexokinase 
enzyme inhibitor used to prevent osteoarthritis72, some antilipolylic 
compounds as nicotinic acid derivatives - acipimox73, and fibrates (ac-
tivate PGC174; melatonin75, SRT1-720  and SRT-2104-direct activa-
tors of SIRT-1; pegvisomant, growth hormone receptor antagonist33; 
AZD8055/INK128, a direct mTOR kinase inhibitor33, tiazolidinedi-
ones agonists PPARs) used in diabetes therapy and obesity13, a lipoic 
acid thiol compound with strong antioxidant properties76 and others. 
Table 1 lists some CRMs and their mechanism of action.
As previously described, CR acts on multiple intracellular signal 
pathways. CR mimetics on the other hand partially induce some of 
these mechanisms. For example, 2DG inhibits glycolysis, thus favor-
ing AMPK and SIRT signaling activity; metformin amplifies AMPK 
signaling, which indirectly leads to autophagy and amplification of 
the mitochondrial turnover, resveratrol increases the activity of SIRT 
and AMPK, etc.77 The likelihood that some compound will stimulate 
all the mechanisms is small and therefore the CRM-„cocktail“ effects 
will be tested, which would have an optimum synergistic effect on life 
expectancy.
Below are the main features of the most famous compounds with 
CRM potential.
Metformin (N,N-dimethylimidocarbonimide diamide), a member 
of the biguanide group, has been using for several decades in type 2 
diabetes mellitus therapy since it inhibits the gluconeogenesis process 
and decreases insulin level78. It has been established that metformin 
has the ability to imitate most CR mechanisms and is presumed to 
be the main target of metformin AMPK79. AMPK activation leads 
to suppressive insulin/IGF-1 and mTOR signaling and activation of 
SIRT-127. It is also considered that alterations in cell signaling occur 
secondary after inhibition of complex I mitochondrial respirato-
ry chain resulting in ATP concentration decrease80. The increased 
AMP/ATP ratio, furthermore, activates AMPK, and consequently 
the transcription factors and the metabolic enzyme of said signaling 
pathways, in order to restore energy to the cells. Hence, they influence 
the processes associated with longevity such as mitochondrial turnover 
autophagy, stress defense, protein synthesis and inflammation81.
The results of metformin research as CRM, are now controversial, 
i.e. effects on longevity are not observed in all species investigated82. 
Controversial results and the possibility of occurrence of lactic acidosis 
with chronic administration of metformin83 point to caution and the 
need to determine optimal metformin dose for the purpose of healthy 
aging and longevity. The results of a human pattern study entitled 
“Targeting Aging with Metformin”, which are underway, should form 
a pattern or paradigm for assessing pharmacological approaches to 
delay or slowdown of aging81.
2-deoxy D-glucose, glucose analog and glycolysis inhibitor, is one of 
the first compounds considered as CRM25. It inhibits the activity of 
the glycolytic enzyme phosphoglucose isomerase thereby preventing 
the conversion of glucose-6-phosphate into fructose-6-phosphate. The 
Mimetic CR (category of compound) Mechanisms of acting
Metformin
(biguanide)
Inhibition of mitochondrial complex I; activation of PI3/AKT cascade; activation of AMPK
2-deoxy-D-glucose 
(glycolytic inhibitor)
Inhibition of phosphoglucose isomerase




Nicotinamide riboside NAD precursor




Table 1. Calorie restriction mimetics 
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result is the energy supply limit in the form of ATP, and the AMP/
ATP ratio increases.  Next, activation of AMPK pathway is followed. 
Thereafter, activation of SIRTs and autophagy (84) occur. It is con-
sidered that 2DG causes delay of age-related dysfunction, and shows 
effects similar to CR85. On some organisms it has been shown that 
2DG can stimulate stress response proteins and heat shock protein 
7086. However, the attitudes of 2DG effect on life extensions differ, 
which is probably the result of differently designed research. A favor-
able effect was generally observed at lower concentrations of 2DG, 
while with increased concentration this compound had a cardiotoxic 
effect in rats87.
Rapamycin [23,27-epoxy-3H-pyrido(2,1-c)(1,4) oxazacyclohentri-
acontine] is a macrolide antibiotic (also known as Sirolimus) with 
immunosuppressive and antiproliferative properties, most commonly 
used in organ transplantation88. The effect of promoting rapamy-
cin’s longevity was first discovered in yeast and later confirmed on 
numerous other organisms, while human-based examinations are still 
to be carried out. Rapamycin has low bioavailability, and in order to 
achieve higher solubility and stability, the authors emphasize the need 
for the development of rapamycin analogues89. Additional reasons for 
the analogs are also the immunosuppressive properties of rapamycin 
and the consequent possibility to develop viral and bacterial diseases. 
In this respect, investigations of the most effective dose of rapamycin 
for healthy aging and longevity are being conducted.
The mechanism by which rapamycin exerts its effect involves inhi-
bition of mTOR signaling90. It is assumed that rapamycin forms a 
heterotrimeric complex with two proteins, FK506 binding protein 
(FKBP)-type peptidyl-prolyl cis-trans-isomerase and the FKBP-rapa-
mycin-associated protein. This heterotrimer can be complexed with 
mTOR and thus inhibit the formation of mTORC1 complexes and 
consequently cell growth and proliferation. Activating of autopha-
gy-related protein 1 (ATG1) can stimulate activation of the autoph-
agy process77. Rapamycin reduces inhibition of SIRT-1 by decreasing 
NF-κB mediated inflammation91.
Resveratrol (3,4,5-trihydroxystilbene) is a natural, vegetable polyphe-
nol compound of the stilbene subgroup, with antioxidant activity 
being most common in grape and red wine92. In 2003, the in vitro 
NIA (National Institute for Aging) screening program confirmed the 
resveratrol property to activate SIRT-1, and model systems demon-
strated that this activation was followed by autophagy93. Significant 
number of articles show that resveratrol prolongs the life of different 
species, but there are opposite opinions94,95. Among others, it has 
been described that resveratrol reduces insulin secretion, increas-
es insulin sensitivity, decreases body fat, increases mitochondrial 
biogenesis and oxidative phosphorylation, increases AMPK activity, 
autophagy and mitophagy, and also NAD/NADH ratio, which 
activates SIRT-155. Although the exact mechanism of action is not 
entirely clear, resveratrol binds to the regulatory N-terminal subunit 
of SIRT-1, leading to conformational change, which in turn results 
in increased deacetylation activity of SIRT-196. Unwanted effects 
of  resveratrol have not yet been recorded except for extremely high 
concentrations97.
Spermidine. The polyamine compound, spermidine is also included 
in CRMs. Studies of the anti-aging effects of spermidine are still 
ongoing and are not quite clear, but seem to be partly related to 
the induction of autophagy98. Spermidine acts as an inhibitor of 
acetyltransferase EP300, endogenous autophagy inhibitor, which acts 
by acetylation of lysine residues within various proteins. Compounds 
used in traditional medicine, for example anacardic acid, curcumin, 
garcinol and epigallocatchin-3-gallate, also inhibit EP30098. In addi-
tion, spermidine exhibits various pleiotropic effects including antioxi-
dative and anti-inflammatory activity, improvement of mitochondrial 
metabolic activity, and improvement of the proteostasis process. The 
undesirable effect of polyamines, including spermidine, is the ability 
to stimulate tumor progression at high concentrations99.
CR-mimicking lifestyle (behavioral) strategies include the limitation 
of macro- or micronutrients (eg. protein or amino acids), periodic 
starvation (including, for example, feeding ad libitum 5 days a week 
and starvation or limiting food intake for two days), intermittent 
starvation (change of day of normal feeding and day of complete re-
striction of food, or minimum food intake) with different recommen-
dations, i.e. restricted feeding and habitual exercise. 
As it is assumed it will not be possible to find a drug that will include 
all pathways/mechanisms of CR without undesirable effects, the 
results of testing of the combination of different CRMs, CRM com-
binations with a specific CR level or other combinations of types will 
be interesting due to balancing the detrimental effects of chronic CR 
regime on one side, and the unwanted CRM effects on the other89,100.
concluSion
The aging process is an inevitable process that is additionally adverse-
ly affected by the development of age-related diseases. In the area of 
geroscience, great efforts have been made to detect the causes and 
mechanisms of this process in order to establish appropriate genetic 
or nutritional/pharmacological interventions for the purpose of 
healthy aging and longevity. This does not seem easy, since the mech-
anisms are networked, ie., there are mutual activating or suppressing 
actions.
The CR has now proved to be a promising intervention in achieving 
that goal. CR promotes life-prolonging processes such as autophagy, 
mitochondrial biogenesis, and ATP production. Although the ideal 
calorie intake is currently unknown and is likely to be different for 
each person, the results of CR research on various model systems 
and types have provided insights into the main signaling pathways of 
healthy aging and longevity.
Some of these pathways have become the main goals or candidates 
for CRM development that could be used for the purpose of healthi-
er aging or postponement of aging-related illnesses. Besides examina-
tions of individual, potential CRM compounds, but also investiga-
tions with their combinations and combinations of CRM and other 
imitation CR strategies are performed. Alternative CR strategies 
occasional starvation, modulation of nutritional input/balanced input 
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of macronutrients, and other effects to be explored in future research. 
It is assumed that different strategies will also have different effects on 
complex pathway signaling participants. It is to be expected, that the 
real direction will be given interdisciplinary research that will define 
the most optimal type of strategy. Undoubtedly, the implementation 
of omics-based approaches such as genomics, transcriptomics, metab-
olomics and proteomics will be of great help.
Discussion about aging as a) normal/partially normal or natural or b) 
partial pathological process is ongoing, and the latest developments in 
gerontology reveal the molecular link between aging and pathological 
conditions. However, many open questions remain about the aging 
process at the molecular level. Generally, it is necessary to try, if pos-
sible, to define more clearly processes that induce aging, ie “natural” 
aging and age-related diseases. The application of CRM on a human 
beings for the purpose of achieving longevity, will only be enabled and 
justified after researches has been carried out on a number of non-hu-
man primate models, which for now have a small number, and after 
considering ethical, economic and social implications.
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